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Abstract 
Background: Worldwide introduction of the FIGO 2000 scoring system has provided an effective 
means to stratify patients with gestational trophoblastic neoplasia (GTN) to single- or multi-agent 
chemotherapy. However, the system is quite elaborate with an extensive set of risk factors. In this 
study, we re-evaluate all prognostic risk factors involved in the FIGO 2000 scoring system and 
examine if simplification is feasible. 
Patients and methods: Between January 2003 and December 2012, 813 patients diagnosed with GTN 
were identified at the Trophoblastic Disease Centre in London and scored using the FIGO 2000. 
Multivariable analysis and stepwise logistic regression were carried out to evaluate if the FIGO 2000 
scoring system could be simplified.  
Results: Of the eight FIGO risk factors only pre-treatment serum human chorionic gonadotropin 
(hCG) levels exceeding 10,000 IU/l (OR = 5.0; CI 2.5-10.4) and 100,000 IU/l (OR = 14.3; CI 4.7-44.1), 
interval exceeding 7 months since antecedent pregnancy (OR = 4.1; CI 1.0-16.2) and tumor size of 
over 5 cm (OR =  2.2; CI 1.3-3.6) were identified as independently predictive for single-agent 
resistance. In addition, increased risk was apparent for antecedent term pregnancy (OR = 3.4; CI 0.9-
12.7) and the presence of 5 or more metastases (OR = 3.5; CI 0.4-30.4), but patient numbers in these 
categories were relatively small. Stepwise logistic regression identified a simplified risk scoring model 
comprising age, pre-treatment serum hCG, number of metastases, antecedent pregnancy and 
interval but omitting tumor size, previous failed chemotherapy and site of metastases. With this 
model only 1 of 725 patients was classified differently from the FIGO 2000 system. 
Conclusion: Our simplified alternative using only five of the FIGO prognostic factors appears to be an 
accurate system for discriminating patients requiring single as opposed to multi-agent 
chemotherapy. Further work is urgently needed to validate these findings.  
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Key message: The current FIGO 2000 scoring system for gestational trophoblastic neoplasia is quite 
elaborate with an extensive set of risk factors. We therefore present a re-evaluation of the FIGO 
2000 and propose a simplified alternative. Using only five of the FIGO risk factors, this alternative 
appears to retain accurate discrimination for patients requiring single- as opposed to multi-agent 
chemotherapy. 
 
  
Introduction 
Gestational trophoblastic disease (GTD) comprises a group of pregnancy related disorders including 
the premalignant complete and partial hydatidiform moles through to the malignant invasive mole, 
choriocarcinoma, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT) 
[1]. The malignant counterparts are often collectively referred to as gestational trophoblastic 
neoplasia (GTN). Fortunately, with the introduction of effective chemotherapy, GTN has become 
highly curable with overall survival rates approaching 99% [1-4]. 
  
Cure for non-PSTT/ETT forms of GTN can often be achieved with single-agent chemotherapy 
comprising either methotrexate (with or without folinic acid rescue) or actinomycin D. However 
some patients require multi-agent chemotherapy most commonly comprising etoposide, 
methotrexate, actinomycin D alternating weekly with cyclophosphamide and vincristine (EMA/CO) to 
achieve long-term remission [4]. Over the years, several important predictors of unfavorable 
prognosis such as serum human chorionic gonadotropin (hCG) levels and site of metastases have 
been proposed [2, 5, 6] to stratify patients between single or multi-agent therapies. These factors 
have formed the basis of a number of different clinical scoring systems [5, 7], used to distinguish GTN 
patients as either having a low- or high-risk of developing resistance to single-agent chemotherapy. 
 
To help facilitate comparison of datasets between international treatment centres, a renewed 
scoring system was introduced in 2000 [8, 9]. The new FIGO 2000 risk scoring system was based on a 
combination of anatomic and pathophysiological features of the disease and was developed with the 
effort of a number of international societies including the International Society for the Study of 
Trophoblastic Diseases (ISSTD), the International Gynaecologic Cancer Society (IGCS) and 
International Fedaration of Gynaecology and Obstetrics (FIGO)[9, 10].  
 
The worldwide introduction of the FIGO 2000 has provided an opportunity to reach agreement on 
classification and subsequent treatment for patients with GTN. However, the system is quite 
elaborate and comprises an extensive set of risk factors, several of which relate to tumor bulk and 
may therefore not be independently prognostic  [2, 6, 11]. A greater number of factors involved will 
likely result in an increased variability in scoring and classification. Especially in a low incidence 
disease like GTN however, global unification is essential to optimize management.  
 
In this study, fifteen years following the introduction of FIGO 2000, we decided to re-evaluate all 
prognostic factors involved in the FIGO 2000 scoring system to determine whether simplification of 
this system is feasible.  
 
  
Materials and methods 
Patients  
All patients diagnosed with GTN between January 2003 and December 2012 were identified from the 
electronic database of the Trophoblastic Disease Centre at Charing Cross Hospital in London. Patients 
with a histopathological diagnosis of PSTT or ETT were excluded, resulting in 813 GTN patients of 
which 725 were low-risk and 88 were high-risk by FIGO 2000 scoring. Uni- and multi-variable analyses 
were conducted for 705 of 725 low-risk patients, since this was the total number of cases where their 
response to single-agent therapy was known. The remaining 20 patients had FIGO score 6 disease 
and either wanted high-risk treatment or were advised to start high-risk treatment because of a very 
high pre-treatment serum hCG typically in excess of 400,000 IU/L [12]. 
 
Management protocols  
Prior to treatment all patients were assigned to low- or high-risk groups in accordance with the FIGO 
2000 scoring system for GTN (Supplementary Table 1). Low-risk patients received single-agent 
methotrexate with folinic acid rescue (50 mg intramuscular MTX on days 1, 3, 5, and 7 and folinic 
acid 15 mg orally on days 2, 4, 6, and 8). In patients developing resistance or unmanageable toxicity, 
therapy was changed to either single-agent actinomycin D (ActD) or multi-agent chemotherapy 
comprising etoposide, methotrexate and actinomycin D alternating weekly with cyclophosphamide 
and vincristine (EMA/CO). The decision to use ActD as opposed to EMA/CO was based on the serum 
hCG level at the point of resistance. Patients with an hCG ≤ 300 IU/L received ActD whilst those > 300 
IU/L were given EMA/CO as previously described [13]. ActD was given as 0.5 mg intravenously on 
days 1-5 every two weeks [13]. Patients with disease resistant to ActD received EMA/CO 
chemotherapy subsequently. High-risk patients received multi-agent chemotherapy with EMA/CO as 
first-line therapy. In patients presenting with very advanced disease, induction low-dose etoposide 
and cisplatin was given prior to commencing either EMA/CO or EP/EMA (etoposide and cisplatin 
alternating weekly with etoposide, methotrexate and actinomycin D). Appropriate adaptation for 
occult or overt CNS disease was provided as previously described  [14, 15]. Disease response and 
resistance to therapy was assessed by serum hCG measurements undertaken twice weekly until hCG 
was normal and then weekly until 6 weeks after completion of chemotherapy using the Charing Cross 
hCG radioimmunoassay as previously described [4].  
 
Statistical analysis 
The predictive value of the prognostic factors for chemoresistance to MTX or ActD was assessed in 
low-risk patients using univariate and multivariable logistic regression.  
Thereafter, a backward stepwise (Wald) logistic regression was carried out for all patients to evaluate 
if simplification of the original FIGO system was feasible. To minimize the number of low-risk patients 
unnecessary subjected to the more aggressive multi-agent chemotherapy with consequent toxicity, 
simplified models were only considered if at least 98% of patients had concordant FIGO classification. 
Guided by the previous results, a small set of modified FIGO models that best resembled 
classification of the original FIGO 2000 was constructed. Finally, with receiver operating characteristic 
(ROC) curves, the discriminating power of the alternative models in comparison to the original FIGO 
classification was evaluated. All statistical analyses were performed with SPSS for windows 22.0. 
 
Results 
Patient characteristics of the 813 patients with GTN are shown in Table 1. Twenty-eight percent of 
low-risk patients eventually needed salvage multi-agent chemotherapy after initial MTX/FA with or 
without subsequent ActD. One death associated with acute renal failure occurred as a result of 
complications during multi-agent therapy for widespread disease.  
 
Table 2 shows the results of the univariate and multivariable analysis performed for low-risk patients 
treated with single-agent chemotherapy. Site of metastases and previous failed chemotherapy were 
not included in the analysis as all patients with widespread metastases or previous failed 
chemotherapy were classified as high-risk patients and therefore not treated with single-agent 
therapy. Tumor size, antecedent term pregnancy, interval and pre-treatment serum hCG were 
significant predictors for single-agent resistance in univariate analysis. In multivariable analysis, pre-
treatment serum hCG levels exceeding 10,000 IU/L (OR = 5.0; CI 2.5-10.4) and 100,000 IU/L (OR = 
14.3; CI 4.7-44.1), interval exceeding 7 months since antecedent pregnancy (OR = 4.1; CI 1.0-16.2) 
and tumor size of over 5 cm (OR =  2.2; CI 1.3-3.6) were all identified as independent predictive 
factors for resistance to single-agent therapy. An increased risk was apparent for antecedent term 
pregnancy (OR = 3.4; CI 0.9-12.7) and the presence of 5 or more metastases (OR = 3.5; CI 0.4-30.4). 
However, numbers in these categories were relatively small.  
 
Using stepwise backwards (Wald) logistic regression, FIGO criteria lacking significant independent 
value were eliminated, identifying three simplified models. In these models 4 (model 2) or 5 (model 1 
and 3) of the original 8 FIGO criteria were sufficient for identical risk classification in 99% of patients 
(Table 3). The discriminating power of these simplified FIGO scoring systems was compared to the 
original FIGO 2000 using ROC analysis. In model 1 and 2, six and seven patients respectively were 
classified differently. In model 3, with the elimination of tumor size, site of metastases and previous 
failed chemotherapy, classification for one patient changed from low-risk to high-risk. None of these 
patients had more than 4 metastases or metastases outside the lungs. Supplementary Table 2 shows 
the characteristics of all eight cases with a different risk classification when using one of the 
simplified alternatives in comparison to the FIGO 2000.  
  
Discussion  
The FIGO 2000 comprises a weighted prognostic scoring system resulting in a calculated total score 
and subsequent classification of GTN patients with low-risk and high-risk of resistance to single-agent 
chemotherapy. Most prognostic factors relate to tumor bulk, it is therefore questionable whether all 
these factors are required for adequate classification of patients [16]. Furthermore, with the use of 
interrelated factors the actual weight for certain items could be overrepresented using FIGO 2000.  
 
With use of uni- and multivariable logistic regression, a smaller selection of risk factors could be 
identified as significant predictors for single-agent resistance [1-4]. In concordance with other 
studies, both tumor size and pre-treatment serum hCG emerge as important prognostic variables in 
our analysis [5, 11]. As all patients with GTN likely undergo imaging with pelvic ultrasound, tumor size 
can be derived quite easily in a non-invasive manner. In some cases, the volume of a trophoblastic 
tumor however may not represent the proportion of viable cells due to variations in the extent of 
necrosis and hemorrhage [17]. Serum hCG is a disease-specific tumor marker, associated with burden 
of disease and is easily measured quantitatively. hCG levels of over 10,000 IU/L and 100,000 IU/L in 
particular reflect strong relations to treatment failure in low-risk patients. As commercially available 
assays for quantification of serum hCG concentrations use different sets of antibodies and often a 
different standard, assay results strongly depend on the type of assay used. Although the effect is 
probably modest with high hCG levels, problems may occur with monitoring of response and follow-
up in the lower range of hCG levels [1, 17, 18]. 
 
While antecedent term pregnancy and interval since diagnosis have been associated with poor 
prognosis in univariate analyses, they however lose their significant prognostic value in some 
multivariable analyses [2, 6, 19]. For interval, the resulting hazard ratio appears non-linear and 
results likely depend on the chosen cutoff time. A sensible cutoff point will probably be beyond 12 
months since diagnosis, as suggested by Powles et al. [20]. In our study only few patients had an 
interval exceeding 7 months, and likewise an increased risk of single-agent resistance was seen. In 
patients with antecedent term pregnancies, we observed an increased risk of single-agent resistance, 
but even in this rather large cohort of patients, numbers in this subcategory remain small. Although 
choriocarcinoma could be considered a surrogate marker for antecedent term pregnancy, the latter 
term is preferred as histological confirmation is not always available. Problems with correct 
identification of the antecedent pregnancy and interval subsequently, can particularly occur when a 
patient has previously experienced an abortion without histological examination.  
 
The effect of advanced age in GTD incidence has been evaluated regularly [21-23]. It’s possible effect 
on the development of GTN and survival however has been under debate[2, 5, 6, 11]. In line with the 
majority of studies, age was not identified as an independent prognostic factor in the present study. 
However, treatment often differs with advanced age, since hysterectomy is a reasonable treatment 
option when fertility preservation is not desired and a reduction of toxicity from chemotherapeutic 
regimens may be profitable. Furthermore, considering all factors required for staging, age is probably 
one with the least possible uncertainty [17]. 
 
For both site of metastases and number of metastases, measurements are highly dependent on the 
used imaging technology used. For practical purposes and uniformity, simple investigation tools such 
as X-ray provide adequate clinical guidance [17]. Only few patients with a high number of metastases 
(5 or more) exist, possible implications on prognosis therefore remain unclear. Furthermore, there is 
wide consensus on the effects of widespread metastases on single-agent resistance and survival [2, 
5, 6, 11]. In this cohort however, patients with widespread metastases were all characterized by a 
total FIGO score of over 10. Simultaneous presence of other prognostic factors has obviated the 
occurrence of misclassification in this group. 
 
We however have to keep in mind that the present FIGO score, whilst only designed for stratifying 
patients between low- and high-risk treatments is also used to identify patients at greatest risk of 
early death within 4 weeks of commencing therapy and late death from multi-drug resistant disease. 
These ultra-high risk patients, present with widespread metastatic disease, reflected by a very high 
FIGO score (>12), are at significant risk for pulmonary, intra-peritoneal or intracranial hemorrhage 
and may benefit from low dose induction chemotherapy. Furthermore, those with liver metastases 
with or without brain metastases are at increased risk of late death [15] Removal of criteria that 
reflect these factors in a simplified system would hinder identification of these patient groups [14]. 
Consequently, the new system will need to be carefully evaluated with sufficient patient numbers in 
the high and ultra-high risk groups.  
 
Consensus exists on the concept of re-staging in case of relapse with full re-assessment of spread of 
disease and previous chemotherapy response. Failure to respond to single-agent therapy already 
justifies the start of a different single-agent regimen or multi-agent therapy depending on hCG value. 
Confusion may however exist on the definition of failed chemotherapy. It would therefore be helpful 
to provide a clear definition on failed chemotherapy with the revised FIGO 2000 (i.e. rise of serum 
hCG after two chemotherapy cycles.  
 It appears that only a small proportion of FIGO 2000 prognostic factors is needed to differentiate 
patients with low- versus high-risk of single-agent resistance. This could lead to a relatively 
straightforward system with a small subset of easily retrievable factors, ideally reducing variability in 
scoring and improving agreement between centers. A simplified model with age, pre-treatment 
serum hCG levels, number of metastases, antecedent pregnancy and interval alone resulted in an 
identical risk classification as the original FIGO 2000 in all but 1 of the 194 low-risk patients that 
needed to switch to high-risk therapy. Tumor size, previous failed chemotherapy and site of 
metastases did not provide much added value.  
 
After fifteen years of experience with the worldwide accepted FIGO 2000, the present study provides 
a useful overview of its design and performance in a large nationwide cohort. Although the number 
of patients with resistance to single-agent therapy in the low-risk group made us inquisitive on 
possible improvements in the performance of FIGO 2000, exploration of possible improvement in 
classification is challenging when only the prognostic factors currently employed in the FIGO 2000 
are considered. Doppler ultrasonography, used to measure uterine vascularity through pulsatility 
index has been suggested as an independent prognostic factor for resistance to single-agent 
chemotherapy [24]. Further improvement by including novel variables such as Doppler pelvic 
ultrasonography should be considered. A renewed evaluation, preferably through international 
research collaboration would be needed to further validate these findings and refine FIGO 2000 into 
a straightforward classification system we could all embrace.  
 
Conclusion 
The total FIGO score is determined by a summation of scores for eight prognostic factors. The 
majority of factors relate to tumor bulk and are not independently prognostic for single-agent 
resistance. Our simplified alternative using only five of the FIGO prognostic factors remains an 
accurate system for discriminating patients requiring single as opposed to multi-agent 
chemotherapy. This simplified alternative would ideally reduce variability in scoring and improve 
agreement between centres. However, further validation is required to ascertain how this system 
performs in distinguishing ultra-high risk and high-risk patients. 
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Table 1 Patient characteristics
 a 
Patient characteristic  Low risk patients (N=725) High risk patients (N=88) 
 Mean (sd) min-max Mean (sd) min-max 
Age (years)  32.2 (8.0) 14-56 34.7 (9.2) 15-62 
Pre-treatment 
10
log  serum hCG (IU/l) 3.8 (1.1) 1-7 4.9 (1.1) 2-7 
Interval (months)  1.8 (2.1) 0-35 10.5 (33.2) 0-242 
Duration of treatment (months) 
b
 1.9 (2.2) 0-15 2.8 (1.6) 0-10 
FIGOscore  2.7 (1.6) 0-6 10.3 (3.9) 7-23 
       
Antecedent pregnancy  Number Percentage Number Percentage 
     Hydatidiform Mole  696 96.0 % 36 40.9 % 
     Miscarriage  17 2.3 % 4  4.5 % 
     Term   12 1.7 % 48 54.5 % 
Tumor size (cm)        
     <3cm   304  41.9 % 11 13.7 % 
     3-5cm   240 33.1 % 13 16.3 % 
     >5cm   152 21.0 % 56 70.0 % 
Site of metastases      
     Vagina   4 0.6 % 4 5.0 % 
     Lung   56 7.7 % 46 57.5 % 
     Liver   - - 6 7.5 % 
     Brain   - - 12 15.0 % 
     Other    - - 5 6.3 % 
Number of metastases      
     None   662 91.4 % 23 28.7 % 
     1-4   58 8.0 % 23 28.7 % 
     5-8   4 0.6 % 7 8.8 % 
     >8   - - 27 33.8 % 
 
a
 For some patients scoring on one or more of the FIGO criteria was unavailable 
b
 Duration of treatment is defined in months until normalization in serum hCG levels was reached  
 
Table 2 Univariate and multivariable analysis of prognostic factors for single-agent resistance 
Variable Rate of single-agent 
resistance (%) 
Odds Ratio  
(95% CI)
a 
Odds Ratio  
(95% CI)
a 
  Univariate  Multivariable 
Age (years)    
     <40 159/572 (27.8%)   
     ≥40 34/133 (25.6%)  0.9 (0.6-1.4) 0.9 (0.6-1.5) 
Antecedent pregnancy    
     Hydatidiform Mole 183/677 (27.0%)   
     Miscarriage 4/17 (23.5%) 0.8 (0.3-2.6) 0.6 (0.1-2.4) 
     Term 6/11 (54.5%)  3.2 (1.0-10.7)
 b
 3.4 (0.9-12.7) 
Interval (months)    
     <4 179/617 (29.0%)   
     4-6 9/73 (12.3%) 0.3 (0.2-0.7)
 b
 1.1 (0.5-2.7) 
     7-12 5/14 (35.7%) 1.4 (0.4-4.1) 4.1 (1.0-16.2)
 b
 
     >12 0/1 (0%) - - 
Pre-treatment serum 
hCG (IU/l) 
   
     <1000 19/167 (11.4%)   
     1000-10.000 28/187 (15%) 1.4 (0.7-2.6) 1.6 (0.8-3.5) 
     10.000-100.000 127/324 (39.2%) 5.0 (3.0-8.5)
 b
 5.0 (2.5-10.4)
 b
 
     >100.000 19/27 (70.4%) 18.5 (7.1-48.0)
 b
 14.3 (4.7-44.1)
b
 
Tumor size (cm)    
     <3cm 55/302 (18.2%)   
     3-5cm 61/232 (26.3%) 1.6 (1.1-2.4)
 b 
0.9 (0.6-1.4) 
     ≥5cm 71/142 (50.0%) 4.5 (2.9-7.0) 
b 
2.2 (1.3-3.6) 
b 
Number of metastases    
     None 172/644 (26.7%)   
     1-4 19/56 (33.9%) 1.4 (0.8-2.5) 1.4 (0.7-2.6) 
     5-8 2/4 (50.0%) 2.7 (0.4-19.6) 3.5 (0.4-30.4) 
     >8 0/0 (0%) - - 
a 
CI: Confidence Interval  
b 
p<0.05 
Table 3 Alternative scoring systems and their performance with FIGO 2000 compared 
Model AUC
a 
True Positive
b 
True Negative
b
 False Positive
b
 False Negative
b
 Sensitivity Specitivity Identical classification 
Original FIGO 2000 1.000 694 73 0 0 1.00 1.00 100% 
Model 1 
Age 
Antecedent pregnancy 
Pre-treatment serum hCG  
Tumor size  
Number of metastases 0.999 693 70 2 
1,2
 
c 
4 
5,6,7,8
 
c 
0.99 0.97 99.1% 
Model 2 
Age 
Antecedent pregnancy 
Pre-treatment serum hCG  
Number of metastases 0.998 720 71 4 
1,2,3,4
 
c 
3 
5,7,8
 
c 
1.00 0.95 99.2% 
Model 3 
Age 
Antecedent pregnancy 
Interval 
Pre-treatment serum hCG  
Number of metastases 1.000 722 73 1 
4
 
b 
0 1.00 0.99 99.9% 
Allowing for the fact that the FIGO 2000 was already used in this particular data, the AUC, sensitivity and specificity for the original FIGO 2000 were 
consequently calculated at 1.0. 
 Risk classification according to the FIGO 2000 was considered ‘gold standard’ 
 For every alternative scoring system the number of discordant patients and corresponding casenumbers are highlighted  
